Clinical Trial Update: hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors

View source ↗

Summary

This update covers results from a completed clinical trial evaluating circulating progastrin (hPG80) as a blood biomarker for high-grade glial tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• High-grade Glioma

Snippet

Sponsor: Centre Jean Perrin | Conditions: Glial Cell Tumors | Status: COMPLETED